7/24/2019 Hemorrhoids SOAP

1/3

(Hemorrhoids) 1

Patient Profile

20 1-2

10 2558

CC: 1-2

HPI: 3

PMH:

SH:

ALL:

SOAP note

Problem: Acute Hemorrhoids

S: 1-2 3 A:

rectum [1]

2

2 (non-pharmacological therapy)

7/24/2019 Hemorrhoids SOAP

2/3

(Hemorrhoids) 2

[1] 2

- proctosedyl ointment (Cinchocaine hydrochloride hydrocortisone)- scheriproct-N ointment (flucotolone pivalate lidocaine)

() IESAC

Drug for hemorrhoid Daflon Venoruton300

Active ingredient 90% micronized

diosmin 10%hesperidin

0- (beta hydroyethyl)

rutosides

CissusquadrangularisKetosterones

Indication Hemorrhoid Hemorrhoid Hemorrhoid

Efficacy Daflon ,, [4]

Annoni F [5]

. Daflon 1 20 5%

[6]

Safety Stomach and

abdominal pain, mild

diarrhea, headache

Nausea, vomiting,

heartburn, epigastric

pain

Headache, flatulence, dry

mouth, diarrhea, insomnia

Adherence Initial: 3x2 pc for 4 days

then 2x2 pc for 3 days

Maintain: 1x2 pc

Initial: 300mg 1x3 pc

Maintain: 300mg 1x2 pc

Dose: 3x3 pc

Cost 155 (15 tab) 95 (10 tab) 130 (100cap)

IESAC daflon

daflon venoruton

Plan:

Goal of therapy

7/24/2019 Hemorrhoids SOAP

3/3

(Hemorrhoids) 3

-

- Therapeutic plan

- 3 3

- proctosedyl ointment/ scheriproct-N ointment

Monitoring

Efficacy: Safety: Headache, flatulence, dry mouth, diarrhea, insomnia

Patient education

-

- 8-10

-

- - 15-30 -

Future plan

Reference

1. . 1. 25562. Lyseng-Williamson KA, Perry CM. Micronised purified flavonoid fraction: a review of its use in chronic

venous insufficiency, venous ulcers and haemorrhoids. Drugs. 2003;63(1):71-100.

3. Annoni F, Boccasanta P et al. Treatment of acute symptoms of hemorrhoid disease with high-dose oral

O-(beta-hydroxyethyl)-rutosides. Minerva med 1986; 77(37): 1663-8

4. . . : . 2549